Radiopharmaceuticals are an important component of modern medicine. On April 22, 2024, the Radiopharmaceutical Innovation and Development Conference was held in Beijing, showcasing the latest achievements in the radiopharmaceutical industry. In recent years, nuclear technology application industries such as "radioactive drugs" and "nuclear medicine" have made positive contributions to promoting sustainable economic development and ensuring people's health and life, playing an increasingly important role. Shen Yanfeng, Chairman of the China Isotope and Radiation Industry Association, Member of the Party Group and Deputy General Manager of China Nuclear Industry Group Co., Ltd., stated that the trend of integrated development of nuclear technology is accelerating its widespread penetration into various fields of the economy and society. Cultivating new quality productive forces represented by the nuclear technology application industry has become a strategic choice to seize the new round of technological revolution and industrial transformation opportunities. In recent years, the domestic radioactive drug industry chain has become increasingly perfect, and multiple multinational pharmaceutical companies have also laid out their presence, continuously expanding the Chinese market. It is expected that the domestic market size of radioactive drugs will reach 9.3 billion yuan by 2025, and further increase to 26 billion yuan by 2030. "We need to explore the impact of human stem cell processes in vivo. At present, there is a" dilemma ". In the view of Wang Guangji, an academician of the CAE Member, we need to use nuclear medicine and nuclear technology to promote the development of stem cell research. I hope everyone can work together to overcome the research on the in vivo composition and drug formation of cell drugs, and promote the industrial development of live cell drugs. Radiopharmaceuticals play an important role in the precise diagnosis and treatment of major diseases such as tumors, cardiovascular and cerebrovascular diseases. Dong Jiahong, an academician of the CAE Member, said that in the future, he believed that under the guidance of Y-90 technology, more patients could be effectively treated. Through the research and application of new nuclides, we aim to drive the development of China's radioactive drug industry and ultimately serve the Healthy China strategy. Isotope technology is the core content of nuclear medicine. "225Ac isotope targeted drug is an advanced radiotherapy technology, which is perfectly complementary to particle beam radiotherapy and should be vigorously developed." Zhao Hongwei, academician of the CAS Member, appealed to the relevant domestic departments for support at the conference. "Radiopharmaceuticals are experiencing the 'Renaissance' and developing very quickly," said Tian Jiahe, chief physician at the First Medical Center of the General Hospital of the People's Liberation Army of China. There are many companies in China that produce radiopharmaceuticals, and drug research and development cannot be solved by a single unit. It needs to be combined with clinical practice to complete it. Everyone needs to cooperate together, which is a basic trend. According to Cheng Zhen, director of the Molecular Imaging Center of the Chinese Academy of Sciences Shanghai Institute of Materia Medica, radioactive drugs have been increasingly recognized. To make good use of radioactive isotopes and truly benefit patients, it is necessary to intersect with multiple disciplines, collaborate with biologists, pharmacists, and different fields. This is the core driving force for the original innovation of radiopharmaceuticals. In the future, more radiopharmaceuticals will enter clinical practice and generate greater value. (Lai Xin She)